Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on "New Starting Point, New Momentum, New Journey," gathering leaders and guests from various sectors including regulatory bodies, industry associations, financial institutions, and media [1] - The 14th "Golden Wisdom Award" results were announced, with Tianshili winning the "Excellence Award in the Pharmaceutical and Biological Industry" [2] Group 1: Award Significance - The "Golden Wisdom Award" aims to establish benchmarks for high-quality development, guiding listed companies to focus on their core businesses, innovate continuously, and fulfill social responsibilities [3] - The award reflects the industry's recognition of Tianshili's core competitiveness and high-quality development achievements, emphasizing its commitment to innovation and industry leadership [4] Group 2: Financial Performance - In the first three quarters of 2025, Tianshili achieved pharmaceutical industrial revenue of 5.709 billion yuan, maintaining a steady growth trend [4] - The net profit attributable to shareholders reached 984 million yuan, representing a year-on-year increase of 16.88%, indicating a steady improvement in profitability [4] Group 3: Innovation and R&D - Tianshili's innovation is a core driver of its high-quality development, with a dual-engine R&D system for innovative traditional Chinese medicine and biopharmaceuticals now entering a phase of significant results [4] - The company has 31 innovative drugs in its pipeline, with nearly 20 traditional Chinese medicines in late clinical stages, showcasing its long-term innovation potential [5] Group 4: Future Outlook - The award signifies industry confidence in Tianshili's "dual-engine" innovation strategy and future growth prospects [6] - Tianshili plans to deepen its investment in innovation, accelerate the conversion of pipeline results, and optimize its core business layout to contribute to public health and the upgrade of the biopharmaceutical industry [6]

Core Viewpoint - The "Qihang·2025 Financial Summit" held in Beijing recognized Tianjin Tianshili as the winner of the "Excellence Award in the Pharmaceutical and Biological Industry," highlighting its achievements in high-quality development and innovation in the pharmaceutical sector [1][4]. Group 1: Award and Recognition - The "Jinzhi Award" aims to set benchmarks for high-quality development, guiding listed companies to focus on their core businesses and innovate continuously [3]. - The award recognizes companies that lead high-quality development in the pharmaceutical and biological industry, emphasizing innovation, clinical value transformation, and health security [3][4]. - Tianjin Tianshili's receipt of the award reflects industry acknowledgment of its core competitiveness and high-quality development results [4][6]. Group 2: Financial Performance - In the first three quarters of 2025, Tianjin Tianshili achieved pharmaceutical industrial revenue of 5.709 billion yuan, maintaining a steady growth trend [4]. - The net profit attributable to shareholders reached 984 million yuan, representing a year-on-year increase of 16.88%, indicating improved profitability [4]. Group 3: Innovation and R&D - Innovation is the core driving force behind Tianjin Tianshili's high-quality development, with a focus on building a dual-engine R&D system for innovative traditional Chinese medicine and biopharmaceuticals [4][5]. - The company has 31 innovative drugs in its pipeline, with nearly 20 traditional Chinese medicines in late clinical stages, showcasing its long-term innovation potential [5]. - Key products include a PD-L1/VEGF dual antibody that is undergoing clinical trials, which may lead to breakthroughs in cancer treatment [5]. Group 4: Future Outlook - The award serves as a recognition of past achievements and reinforces confidence in Tianjin Tianshili's dual-engine innovation strategy and future growth prospects [6]. - The company plans to deepen investment in innovation, accelerate the conversion of pipeline results, and optimize its core business layout to contribute to public health and the upgrade of the biopharmaceutical industry [6].

证券代码：600535 证券简称：天士力 编号：临 2025-080 号 天士力医药集团股份有限公司 关于变更公司电子邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）根据实际工作需要，对公 司电子邮箱进行变更，具体情况如下： 变更前的公司电子邮箱：stock@tasly.com 变更后的公司电子邮箱：stock@taslypharma.com 除上述变更外，公司办公地址、联系电话等其他联系方式保持不变。变更后的 电子邮箱自本公告披露之日起正式启用，原邮箱地址同步停用，敬请广大投资者注 意。由此给投资者带来的不便，敬请谅解。欢迎广大投资者通过新的电子邮箱与公 司沟通交流。 特此公告。 天士力医药集团股份有限公司董事会 2025 年 12 月 27 日 1 ...

内蒙古建中律师事务所 关于天士力医药集团股份有限公司 2025 年第六次临时股东会的法律意见书 2025 内建中券意字第 28 号 致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师刘弘、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第六次临时股东会（以下称"本 次股东会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东会规则》（以下称"《股东会规则》"）等法律、法规和规范性文件以及《天 士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本次股东 会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合法有效性 出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东会所涉及的有关事项及文 件资料进行了必要的核查和验证，且贵公司已对前述资料的真实性和准确性向本 所作了保证。 本法律意见书仅供贵公司为本次股东会的适当目的使用，不得被任何人用于 其他任何目的。 本所同意贵公司将本法律 ...

2025年第六次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 证券代码：600535 证券简称：天士力 编号：临2025-079号 天士力医药集团股份有限公司 一、 会议召开和出席情况 (一) 股东会召开的时间：2025 年 12 月 26 日 (二) 股东会召开的地点：天士力医药集团股份有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 566 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 721,099,203 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 50.8084 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事 会召集，根据《公司章程》有关规定，由董事长周辉女士现场主持本次会议。会议 的召集、召开符 ...

Group 1 - The clinical trial for Tianjin Tasly Pharmaceutical Group Co., Ltd.'s allogeneic adipose-derived mesenchymal stem cell injection (B2065) for treating acute ischemic stroke has been initiated, with the trial registration number CTR20255104 and the first public information date set for December 26, 2025 [1] - The drug is administered via intravenous infusion in three dosage groups: 1 bag, 3 bags, and 9 bags, with an infusion time of approximately 20 minutes (±2 minutes) per bag, and the treatment is a single administration [1] - The primary objective of the trial is to evaluate the safety and tolerability of B2065, while secondary objectives include assessing the preliminary clinical efficacy and exploring the mechanism and immunogenicity of B2065 [1] Group 2 - The main endpoints of the trial include the incidence of dose-limiting toxicities (DLT) during the dose escalation phase, adverse events, vital signs, all-cause mortality rates at 14 days, 12 months, and 24 months, and tumor formation observations at 6 months and 24 months [2] - Secondary endpoints consist of the proportion of participants with mRS scores of 0-2 and 0-1 at different time points, the proportion of participants with a decrease in NIHSS score of ≥4 (NIHSS score ≤1), the proportion of participants with BI scores of 95-100, and EQ-5D-5L scores [2] - The current status of the trial is ongoing (not yet recruiting), with a target enrollment of 36 participants [2]

Group 1 - The core point of the article is that Lisheng Pharmaceutical (002393) announced through an interactive platform that its subsidiary, Central Pharmaceutical, holds a 12.15% stake in Tian Shi Li (600535) Biopharmaceutical Industry Group Co., Ltd [1]

Investment Rating - The report indicates a gradual recovery in the food and beverage sector, suggesting a positive outlook for investment opportunities in the industry [6]. Core Insights - The beverage market is experiencing a surge in demand for health-oriented products, particularly turmeric drinks and low-GI foods, driven by younger consumers' health consciousness [2][10]. - The approval of elderberry anthocyanins as a new food ingredient is expected to unlock a significant market potential, with a projected global market size of $960 million by 2027 [4]. - The report highlights the ongoing price wars in the beverage industry, with major brands signaling a trend towards price reductions, which may impact profit margins across the supply chain [9]. Industry Trends - The popularity of turmeric drinks among young consumers is attributed to their perceived health benefits, despite concerns over taste and sugar content [2]. - The rise of the health economy is evident, with a significant increase in sales of health-related products, such as herbal teas and functional foods, particularly among millennials and Gen Z [2]. - The elderberry anthocyanins market is anticipated to grow rapidly, with opportunities for product innovation in immune support and gut health [4]. - The low-GI food market is projected to reach ¥176.2 billion by 2024, driven by increasing health awareness and the prevalence of diabetes among younger populations [10]. - The beverage industry is facing a structural shift, with a focus on "precision" beverages that cater to specific consumer needs and preferences [14]. Brand Dynamics - Kunlun Mountain Mineral Water has entered a strategic partnership to expand its market presence in Hong Kong, leveraging local resources and distribution channels [16]. - Jiahe Foods is transitioning from a contract manufacturer to a consumer brand, facing challenges in profitability due to rising raw material costs and increased marketing expenses [19]. - Vitasoy International reported a decline in revenue, particularly in the mainland market, as competition in the plant-based milk sector intensifies [20]. - Tian Shili's "medical-grade" sugar-free tea has achieved a high repurchase rate by targeting pre-diabetic consumers, showcasing the potential for functional beverages in the health market [21]. - The new brand "Bie Xiang Bao Bao" has gained traction in the sugar-free tea market, achieving significant sales growth through innovative product offerings [22].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： ●被担保人：贝克诺顿（浙江）制药有限公司（以下简称"贝克浙江"）、昆药商业（昭通）医药有限公 司（以下简称"昭通医药"）。上述被担保人分别为华润三九医药股份有限公司（以下简称"华润三九"） 控股子公司昆药集团股份有限公司（以下简称"昆药集团"）下属全资子公司昆明贝克诺顿制药有限公司 （以下简称"贝克制药"）、昆药集团医药商业有限公司（以下简称"昆药商业"）的全资子公司，不存在 关联担保。 ●本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为1,000万元，累计 已实际为其提供的担保余额为1,500万元。 ●特别风险提示：本次被担保人昭通医药为资产负债率超过70%的公司，敬请投资者注意相关风险。 ■ 以上被担保人，信用状况良好，不属于失信被执行人，列示财务状况为被担保人公司单体数据。 ●是否在前期预计额度内：是 ●本次担保是否有反担保：不适用 ●对外担保逾期的累计数量：无 二、被担保公司情况 （一）基本情况 1、贝克诺顿（浙江 ...

Core Viewpoint - The initial public offering (IPO) of Huazhang Biotech-B (02396) on December 22, 2025, experienced significant volatility, with the stock price dropping as much as 29.32% by the end of the trading day, which was below investor expectations given its status as the "first PDGF stock in Hong Kong" [1][2][15] Group 1: IPO Performance - On the first trading day, Huazhang Biotech's stock opened significantly lower, with a maximum drop of 17.80% within the first 10 minutes, reaching a low of 31.4 HKD [1] - The stock price rebounded briefly but ultimately closed at 27.00 HKD, marking a total decline of 29.32% [1] - The company had a substantial oversubscription rate of 791.95 times during the IPO, indicating strong initial interest despite the poor first-day performance [4][7] Group 2: Financial Details - The IPO involved the global issuance of 17.6488 million H-shares, with 90% allocated for international sale and 10% for public offering, raising approximately 674 million HKD [4] - The offering price was set at the lower end of the range at 38.20 HKD per share, with a total fundraising target of about 6.74 billion HKD [5] - The company reported minimal revenue of 47,200 HKD and 26,100 HKD for 2023 and 2024, respectively, primarily from research services, while incurring significant net losses of 1.05 billion HKD, 2.12 billion HKD, and 1.35 billion HKD over the same period [15] Group 3: Market Context and Product Pipeline - Huazhang Biotech focuses on developing and commercializing protein-based therapies, particularly in the wound healing sector, with core products Pro-101-1 and Pro-101-2 targeting burn injuries and diabetic foot ulcers [12][14] - The Chinese diabetes market is projected to grow from 4.7 billion USD in 2023 to 9.3 billion USD by 2032, with a compound annual growth rate (CAGR) of 7.9% [13][14] - The company is in the clinical trial stages for its products, with Pro-101-1 expected to submit an IND application to the FDA in Q1 2026 [14]